Approaches To Indication-Based Pricing For Cancer Drugs Offered In JAMA Article
In most cases, application of the approaches would lead to a reduction in price, sometimes substantially, according to a set of hypothetical scenarios developed by author Peter Bach of Memorial Sloan Kettering.
You may also be interested in...
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.
Pink Sheet reporter and editors discuss the CMS coverage decision for Biogen and Eisai’s Alzheimer’s treatment Aduhelm, the FDA conducting fewer advisory committee meetings in 2021 and the Defense Department’s efforts to increase domestic drug production.